Evidence map›Paper›PMID 25849367›Full record

ArticlePloS one2015

Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.

Nirmin Alsahafi, Olfa Debbeche, Joseph Sodroski, Andrés Finzi

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.Microbiology and molecular biology reviews : MMBR · 2016
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Nirmin AlsahafiDepartment of Microbiology and Immunology, McGill University, Montreal, H3A 2B4 Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, H2X 0A9, Québec, Canada.
Olfa DebbecheCentre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, H2X 0A9, Québec, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, H3C 3J7 Quebec, Canada.
Joseph SodroskiDepartment of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States of America; Department of Microbiology & Immunobiology, Harvard Medical School, Boston, Massachusetts, 02115, United States of America; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, 02115, United States of America.
Andrés FinziDepartment of Microbiology and Immunology, McGill University, Montreal, H3A 2B4 Quebec, Canada; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, H2X 0A9, Québec, Canada; Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montréal, H3C 3J7 Quebec, Canada.
Centre Hospitalier de l’Université de Montréal · CADana-Farber Cancer Institute · USMcGill University · CA

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Understanding Envelope Function in HIV-1 Infection: The Design, Synthesis and Validation of Small Molecule HIV-1 Env InhibitorsP01GM056550 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ABRAMS, CAMERON F · 1997 to 2018
$31.2M
HIV-1 ENVELOPE GLYCOPROTEINSR37AI024755 · NIAID · DANA-FARBER CANCER INSTITUTE · PI SODROSKI, JOSEPH G · 1996 to 2015
$11.6M
Single-particle Reconstruction of HIV-1 Envelope Glycoprotein TrimersR01AI093256 · NIAID · DANA-FARBER CANCER INST · PI SODROSKI, JOSEPH G · 2011 to 2015
$2.2M
ROLE OF THE HTLV-III ENVELOPE GLYCOPROTEIN IN VIRUSR01AI024755 · NIAID · DANA-FARBER CANCER INSTITUTE · PI SODROSKI, JOSEPH G · 1987 to 1995
–
Canadian Institutes of Health Research 119334Canadian Institutes of Health Research 134117NIAID NIH HHS AI100645NIAID NIH HHS AI24755NIAID NIH HHS R01 AI093256NIAID NIH HHS R37 AI024755NIAID NIH HHS UM1 AI100645NIGMS NIH HHS P01 GM056550
6 · The paper itself

Abstract

The mature human immunodeficiency virus (HIV-1) envelope glycoprotein (Env) trimer is produced by proteolytic cleavage of a precursor and consists of three gp120 exterior and three gp41 transmembrane subunits. The metastable Env complex is induced to undergo conformational changes required for virus entry by the binding of gp120 to the receptors, CD4 and CCR5/CXCR4. An isoleucine-to-proline change (I559P) in the gp41 ectodomain has been used to stabilize soluble forms of HIV-1 Env trimers for structural characterization and for use as immunogens. In the native membrane-anchored HIV-1BG505 Env, the I559P change modestly decreased proteolytic maturation, increased the non-covalent association of gp120 with the Env trimer, and resulted in an Env conformation distinctly different from that of the wild-type HIV-1BG505 Env. Compared with the wild-type Env, the I559P Env was recognized inefficiently by polyclonal sera from HIV-1-infected individuals, by several gp41-directed antibodies, by some antibodies against the CD4-binding site of gp120, and by antibodies that preferentially recognize the CD4-bound Env. Some of the gp120-associated antigenic differences between the wild-type HIV-1BG505 Env and the I559P mutant were compensated by the SOS disulfide bond between gp120 and gp41, which has been used to stabilize cleaved soluble Env trimers. Nonetheless, regardless of the presence of the SOS changes, Envs with proline 559 were recognized less efficiently than Envs with isoleucine 559 by the VRC01 neutralizing antibody, which binds the CD4-binding site of gp120, and the PGT151 neutralizing antibody, which binds a hybrid gp120-gp41 epitope. The I559P change completely eliminated the ability of the HIV-1BG505 Env to mediate cell-cell fusion and virus entry, and abolished the capacity of the SOS Env to support virus infection in the presence of a reducing agent. These results suggest that differences exist between the quaternary structures of functional Env spikes and I559P Envs.

Indexed as

Antibodies, NeutralizingCD4 AntigensDisulfidesHEK293 CellsHIV-1HIV Envelope Protein gp120HIV Envelope Protein gp41HumansMutagenesis, Site-DirectedProtein BindingProtein MultimerizationProtein Structure, TertiaryVirus InternalizationAntibodies, NeutralizingCD4 AntigensDisulfidesHIV Envelope Protein gp120HIV Envelope Protein gp41

Identifiers

PMID25849367
PMCPMC4388519
OpenAlexW1995989459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.